Drug Type Antibody oligonucleotide conjugates  | 
Synonyms anti-ENT2 mAb/RIG-I agonist (Gennao/Yale university), GMAB-D31N/3pRNA (Gennao/Yale university)  | 
Target  | 
Action inhibitors, stimulants  | 
Mechanism ENT2 inhibitors(solute carrier family 29 member 2 inhibitors), RIG-I stimulants(Retinoic acid-inducible gene I stimulants)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Melanoma | Preclinical | United States   | - | 






